NCT06718153 Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation
| NCT ID | NCT06718153 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Hepatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-10-23 |
| Primary Completion | 2025-05-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-10-23 with a primary completion date of 2025-05-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The presence of certain mutations in HCC, such as TERT and TP53, have a suspected or proven prognostic role in resected patients, but lack a morphological or immunophenotypic counterpart, which would allow us to define which tumours are rationally candidate for molecular biology analysis. The identification of a histological and immunohistochemical algorithm to determine which HCCs to take to NGS for prognostic purposes will save time and economic costs in the laboratory by rationalising available resources. In the future, the application of the immunohistochemical and molecular algorithm on biopsy could allow better prognosis and predictivity even before surgery/therapy.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Patients resected for HCC * Availability of NGS data * Availability of paraffin material for immunohistochemistry investigations Exclusion Criteria: * None
Contact & Investigator
Francesco Vasuri, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06718153 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06718153 currently recruiting?
Yes, NCT06718153 is actively recruiting participants. Contact the research team at francesco.vasuri2@unibo.it for enrollment information.
Where is the NCT06718153 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06718153 clinical trial?
NCT06718153 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Francesco Vasuri, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.